Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
VUEWAY should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The clinical benefit of VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of VUEWAY (gadopiclenol) at a dose of 0.05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that VUEWAY (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
Avis rectifié en date du 26/11/2024
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
mLrRSU6L3eGtp0yd
